Onglyza May Increase Death Rate

Posted on August 4, 2016

According to a preliminary data review by the U.S. Food and Drug Administration (FDA), AstraZeneca’;s diabetes drug Onglyza (saxagliptin) may be linked to an increased death rate. A study of more than 16,000 patients had previously shown that Onglyza users had an increased risk of hospitalization due to heart failure, but now the FDA has found that the medication may be an increased risk of death from all causes. Onglyza is in a class of medications known as dipeptidyl peptidase-4 inhibitors that work by helping the body produce more insulin to lower blood sugar. Similar studies of another dipeptidyl peptidase-4 inhibitor medication, Takeda’;s Nesina (alogliptin), did not show an increased risk of death.

The FDA didn’t link Onglyza use to any one cause of death, just that it showed “a significantly increased risk of all-cause mortality.” The agency also said the causes of death were “multifactorial” and that many of the patients may have been suffering from multiple, serious health issues.

If you have lost a loved one who was treated with Onglyza, or if you, yourself, have suffered any side effects while being treated with the medication, you may be able to pursue significant compensation. To find out more about your legal rights and options, you’ll want to consult a skilled pharmaceutical litigation attorney. The legal team at the law offices of Farah & Farah can examine the facts in your case and recommend the right course of action to take. If you wish to file a lawsuit on behalf of yourself or a loved one, Farah & Farah’s attorneys can represent you throughout the entire legal proceedings, including settlement litigation and trial.

Farah & Farah is aggressive and tenacious, and will fight to get you and your family the settlement that is deserved. We are currently investigating Onglyza wrongful death related claims nationwide. Call (800) 533-3555 for your free consultation.


  • This field is for validation purposes and should be left unchanged.